CSI Appoints Dr. Jeffery W. Chambers as Chief Medical Officer

March 4, 2022—Cardiovascular Systems, Inc. (CSI) announced that it has appointed Jeffery W. Chambers, MD, as Chief Medical Officer.

According to the company, Dr. Chambers was the Primary Investigator for the ORBIT II study, which served as the company’s pivotal trial supporting the premarket approval for the use of orbital atherectomy in coronary arteries. He has served as a consultant in connection with CSI’s product development, quality assurance, medical affairs, and clinical research.

Since 1995, Dr. Chambers has been employed at the Metropolitan Heart and Vascular Institute in Minneapolis, Minnesota. He is a Fellow at The American College of Cardiology and is a member of The Society for Cardiovascular Angiography and Interventions. The company noted that Dr. Chambers is also a serial entrepreneur with numerous issued patents, some of which are associated with devices that are commercially available.

Dr. Chambers received his medical degree from Wayne State University in Detroit, Michigan, and completed his residency in Internal Medicine and fellowships in cardiovascular disease and interventional cardiology at the University of Minnesota in Minneapolis, Minnesota.

In the company’s press release, Dr. Chambers commented, “I am excited to join CSI and I look forward to working with the team to bring innovative and important technologies to underserved patient populations. In doing so, together, we will improve the health of people with coronary and peripheral artery disease and fulfill our mission.”

Scott Ward, CSI’s Chairman, President, and Chief Executive Officer, stated, “CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology.”

Mr. Ward continued, “Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable perspective to CSI as we seek to successfully develop and commercialize everolimus drug-coated balloons, intravascular lithotripsy balloons, thrombectomy devices and mechanical circulatory support products.”